{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:17:46Z","timestamp":1782569866914,"version":"3.54.5"},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Federal Institute for Drugs and Medical Devices","award":["V-16703\/68502\/2016-2020"],"award-info":[{"award-number":["V-16703\/68502\/2016-2020"]}]},{"name":"University Hospital of Bonn","award":["V-16703\/68502\/2016-2020"],"award-info":[{"award-number":["V-16703\/68502\/2016-2020"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0230632","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T17:36:56Z","timestamp":1585244216000},"page":"e0230632","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-051X","authenticated-orcid":true,"given":"Diana","family":"Dubrall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Carolin","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"issue":"4","key":"pone.0230632.ref001","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.iac.2006.08.001","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema","volume":"26","author":"JB Byrd","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"pone.0230632.ref002","first-page":"298","article-title":"Drug-induced angioedema; Focus on bradykinin","volume":"69","author":"B Sachs","year":"2018","journal-title":"Hautarzt"},{"issue":"1","key":"pone.0230632.ref003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.iac.2016.08.011","article-title":"The Angiotensin-Converting-Enzyme-Induced Angioedema","volume":"37","author":"M Bas","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"pone.0230632.ref004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2500\/ajra.2014.28.3989","article-title":"Life-threatening angioedema induced by angiotensin-converting enzyme inhibitors: characteristics and risk factors","volume":"28","author":"T Stauber","year":"2014","journal-title":"Am J Rhinol Allergy"},{"issue":"6","key":"pone.0230632.ref005","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"DR Miller","year":"2008","journal-title":"Hypertension"},{"issue":"5","key":"pone.0230632.ref006","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14740338.5.5.643","article-title":"Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it","volume":"5","author":"L Beltrami","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"pone.0230632.ref007","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/ACI.0b013e328362b835","article-title":"Angioedema induced by angiotensin-converting enzyme inhibitors","volume":"13","author":"P Campo","year":"2013","journal-title":"Curr Opin in Allergy Clin Immunol"},{"issue":"20","key":"pone.0230632.ref008","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system","volume":"172","author":"S Toh","year":"2012","journal-title":"Arch Intern Med"},{"issue":"4","key":"pone.0230632.ref009","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","article-title":"Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department","volume":"100","author":"A Banerji","year":"2008","journal-title":"Ann Allerg Asthma Immunol"},{"issue":"10","key":"pone.0230632.ref010","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/all.12680","article-title":"Angioedema induced by cardiovascular drugs: new players join old friends","volume":"70","author":"M Bas","year":"2015","journal-title":"Allergy"},{"issue":"1","key":"pone.0230632.ref011","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2222.2009.03323.x","article-title":"Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors","volume":"40","author":"T Hoover","year":"2010","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"pone.0230632.ref012","first-page":"14","article-title":"Drug-induced angioedema","volume":"1","author":"AP Kaplan","year":"2011","journal-title":"Journal of Angioedema"},{"issue":"1","key":"pone.0230632.ref013","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.107.096552","article-title":"Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor\u2013Associated Angioedema","volume":"51","author":"JB Byrd","year":"2008","journal-title":"Hypertension"},{"issue":"12","key":"pone.0230632.ref014","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1046\/j.1440-1681.2001.03564.x","article-title":"The Kallikrein\u2013Kinin System In Humans","volume":"28","author":"DJ Campbell","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"9117","key":"pone.0230632.ref015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"351","author":"J Nussberger","year":"1998","journal-title":"The Lancet"},{"key":"pone.0230632.ref016","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/jch.13097","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature","volume":"19","author":"T Brown","year":"2017","journal-title":"J Clin Hypertens"},{"issue":"1","key":"pone.0230632.ref017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/01.HYP.33.1.323","article-title":"Estrogen Regulation of Angiotensin-Converting Enzyme mRNA","volume":"33","author":"PE Gallagher","year":"1999","journal-title":"Hypertension"},{"issue":"10","key":"pone.0230632.ref018","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/ene.12472","article-title":"Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use","volume":"21","author":"SY Lin","year":"2014","journal-title":"Eur J Neurol"},{"issue":"14","key":"pone.0230632.ref019","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"JB Kostis","year":"2005","journal-title":"Arch Intern Med"},{"issue":"2","key":"pone.0230632.ref020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjmed.2014.07.011","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema","volume":"128","author":"S Bezalel","year":"2015","journal-title":"Am J Med"},{"issue":"4","key":"pone.0230632.ref021","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","article-title":"An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors","volume":"10","author":"T Morimoto","year":"2004","journal-title":"J Eval Clin Pract"},{"issue":"2","key":"pone.0230632.ref022","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/cea.13326","article-title":"Pharmacogenetics of angiotensin-converting enzyme inhibitor-induced angioedema","volume":"49","author":"Y Liau","year":"2019","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"pone.0230632.ref023","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin\u2013Angiotensin System Inhibitors","volume":"110","author":"H Makani","year":"2012","journal-title":"Am J Cardiol"},{"issue":"10","key":"pone.0230632.ref024","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1751-7176.2010.00352.x","article-title":"Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension","volume":"12","author":"WB Withe","year":"2010","journal-title":"The Journal of Clinical Hypertension"},{"issue":"9204","key":"pone.0230632.ref025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","article-title":"Angiotensin II receptor antagonists","volume":"355","author":"M Burnier","year":"2000","journal-title":"The Lancet"},{"issue":"2","key":"pone.0230632.ref026","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1470320313491997","article-title":"In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting-enzyme","volume":"16","author":"K Joseph","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Sys"},{"issue":"6","key":"pone.0230632.ref027","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1527-5299.2002.01529.x","article-title":"Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy","volume":"8","author":"DA Sica","year":"2002","journal-title":"Congest Heart Fail"},{"issue":"18","key":"pone.0230632.ref028","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1001\/archinte.158.18.2063","article-title":"Angioneurotic edema attributed to the use of losartan","volume":"158","author":"EW van Rijnsoever","year":"1998","journal-title":"Arch Intern Med"},{"issue":"8","key":"pone.0230632.ref029","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/archinte.164.8.910","article-title":"Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment","volume":"164","author":"M Cicardi","year":"2004","journal-title":"Arch Intern Med"},{"key":"pone.0230632.ref030","first-page":"3021","article-title":"ESC\/ESH Arterial Hypertension (Management of) Guidelines: ESC Clinical Practice Guidelines","volume":"39","author":"B Williams","year":"2018","journal-title":"European Heart Journal"},{"issue":"12","key":"pone.0230632.ref031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002315","article-title":"US Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the Future","volume":"4","author":"LC Kovell","year":"2015","journal-title":"Journal of the American Heart Association"},{"key":"pone.0230632.ref032","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-54630-7","volume-title":"Arzneiverordnungsreport 2017","author":"U Schwabe","year":"2017"},{"issue":"5","key":"pone.0230632.ref033","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00103-013-1667-8","article-title":"Arzneimittelanwendung von Erwachsenen in Deutschland\u2013Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1)","volume":"56","author":"H Knopf","year":"2013","journal-title":"Bundesgesundheitsbl"},{"key":"pone.0230632.ref034","unstructured":"European Medicines Agency. EudraVigilance: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance"},{"key":"pone.0230632.ref035","unstructured":"Federal Institute for Drugs and Medical Devices (BfArM). http:\/\/www.bfarm.de\/EN\/Home\/home_node.html"},{"key":"pone.0230632.ref036","unstructured":"Paul-Ehrlich-Institut (PEI). http:\/\/www.pei.de\/EN\/home\/node.html"},{"issue":"23","key":"pone.0230632.ref037","first-page":"393","article-title":"Frequent Adverse Drug Reactions, and Medication Groups under Suspicion","volume":"115","author":"D Dubrall","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"pone.0230632.ref038","unstructured":"Gesetz \u00fcber den Verkehr mit Arzneimitteln (Arzneimittelgesetz -AMG). Arzneimittelgesetz in der Fassung der Bekanntmachung vom 12. Dezember 2005 (BGBl. I S. 3394), das zuletzt durch Artikel 5 des Gesetzes vom 4. Mai 2017 (BGBl. I S. 1050) ge\u00e4ndert worden ist."},{"key":"pone.0230632.ref039","unstructured":"Federal Institute for Drugs and Medical Devices. European Database on Adverse Drug Reaction Reports: https:\/\/www.bfarm.de\/EN\/Drugs\/vigilance\/ReportingRisks\/uawDB\/_node.html;jsessionid=1BB26673C3179E94EDEDF2652336A714.1_cid319."},{"key":"pone.0230632.ref040","unstructured":"European Medicines Agency. EudraVigilance system overview. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/eudravigilance-system-overview"},{"key":"pone.0230632.ref041","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: Anatomical Therapeutical Chemical (ATC) Classification. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed: 13 December 2018."},{"key":"pone.0230632.ref042","unstructured":"German Institute of Medical Documentation and Information (DIMDI). ATC-Clissification. https:\/\/www.dimdi.de\/dynamic\/en\/drugs\/atc-classification\/index.html"},{"key":"pone.0230632.ref043","unstructured":"European Medicines Agency. EudraVigilance User Manual: Individual Case Safety Report form: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/eudravigilance-user-manual-individual-case-safety-report-form-version-11_en.pdf. Version 1.1. 22 January 2018."},{"key":"pone.0230632.ref044","unstructured":"MedDRA: Medical Dictionary for Regulatory Activities. Introductory Guide MedDRA Version 21.0. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_21_0_english.pdf. Accessed: March 2018."},{"key":"pone.0230632.ref045","unstructured":"MedDRA: Medical Dictionary for Regulatory Activities. Introductory Guide for Stanardised MedDRA Queries (SMQs) Version 16.0. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_16_0_english.pdf. Accessed March 2013."},{"issue":"9237","key":"pone.0230632.ref046","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"R Edwards","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"pone.0230632.ref047","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","article-title":"vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues","volume":"37","author":"T Bergvall","year":"2014","journal-title":"Drug Saf"},{"key":"pone.0230632.ref048","first-page":"1","article-title":"Drug-induced anaphylactic reactions in children: A retrospective analysis of 159 validated spontaneous reports","author":"B Sachs","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0230632.ref049","unstructured":"Statistische Bundesamt. Bev\u00f6lkerung: https:\/\/www.destatis.de\/DE\/ZahlenFakten\/GesellschaftStaat\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen_\/lrbev01.html%20D_STATIS"},{"key":"pone.0230632.ref050","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00228-011-1014-7","article-title":"Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?","volume":"67","author":"T Grimmsmann","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0230632.ref051","unstructured":"European Medicines Agency. EudraVigilance: security principles and responsibilities. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/eudravigilance-security-principles-responsibilities"},{"key":"pone.0230632.ref052","unstructured":"European Medicines Agency. Access to EudraVigilance data. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/access-eudravigilance-data."},{"key":"pone.0230632.ref053","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00105-018-4347-7","article-title":"Genderaspekte bei Angio\u00f6edemen","volume":"70","author":"G Bindke","year":"2019","journal-title":"Der Hautarzt"},{"issue":"5\u20136","key":"pone.0230632.ref054","first-page":"698","article-title":"Prevalence of allergic diseases in Germany. Results of the German Health Interview and Examination Survey for Adults (DEGS1)","volume":"56","author":"U Langen","year":"2013","journal-title":"Bundesgesundheitsbl"},{"issue":"2","key":"pone.0230632.ref055","first-page":"59","article-title":"Rauchen bei Erwachsenen in Deutschland","volume":"2","author":"J Zeiher","year":"2017","journal-title":"Journal of Health Monitoring"},{"key":"pone.0230632.ref056","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1038\/s41598-018-29965-8","article-title":"MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia","volume":"8","author":"A Navin\u00e9s-Ferrer","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0230632.ref057","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12245-017-0141-z","article-title":"Angioedema in the emergency department: a practical guide to differential diagnosis and management","volume":"10","author":"JA Bernstein","year":"2017","journal-title":"Int J Emerg Med"},{"key":"pone.0230632.ref058","first-page":"6","article-title":"Ulmer Notfallalgorithmus: Therapie von Medikamenten-induzierten, Bradykinin vermittelten Angio\u00f6demen","volume":"97","author":"J Hahn","year":"2018","journal-title":"Laryngo Thino Otol"},{"issue":"2","key":"pone.0230632.ref059","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/hy0202.103054","article-title":"Dipeptidyl peptidase IV activity in patients with ACE-inhibitor associated angioedema","volume":"39","author":"J Lefebvre","year":"2002","journal-title":"Hypertension"},{"issue":"2","key":"pone.0230632.ref060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaci.2007.04.012","article-title":"Dipeptidyl peptidase IV deficiency increases suspectibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema","volume":"120","author":"JB Byrd","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"pone.0230632.ref061","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00415-005-0789-9","article-title":"Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke","volume":"252","author":"ST Engelter","year":"2005","journal-title":"J Neurol"},{"issue":"5","key":"pone.0230632.ref062","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jnnp-2014-308097","article-title":"Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke","volume":"86","author":"R Hurford","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"pone.0230632.ref063","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1212\/01.WNL.0000058840.66596.1A","article-title":"Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke","volume":"60","author":"MD Hill","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"pone.0230632.ref064","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.07371009","article-title":"Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients","volume":"5","author":"M Duerr","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0230632.ref065","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1398-9995.2010.02398.x","article-title":"Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use","volume":"65","author":"JB Byrd","year":"2010","journal-title":"Allergy"},{"issue":"3","key":"pone.0230632.ref066","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"NJ Brown","year":"2009","journal-title":"Hypertension"},{"key":"pone.0230632.ref067","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-5491.2010.02973.x","article-title":"Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report","volume":"27","author":"S Skalli","year":"2010","journal-title":"Diabetic Medicine"},{"issue":"3","key":"pone.0230632.ref068","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","article-title":"Epidemiology and Incidence of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record","volume":"5","author":"A Banerji","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"pone.0230632.ref069","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","article-title":"Physicians\u2018 knowledge and atiitudes regarding the spontaenous reporting system for adverse drug reactions","volume":"55","author":"J Hasford","year":"2002","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"pone.0230632.ref070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-Reporting of Adverse Drug Reactions","volume":"29","author":"L Hazell","year":"2006","journal-title":"Drug Saf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0230632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T23:01:40Z","timestamp":1722639700000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0230632"}},"subtitle":[],"editor":[{"given":"Masaki","family":"Mogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":70,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0230632","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]}}}